-+ 0.00%
-+ 0.00%
-+ 0.00%

Viatris Wins European Medicines Agency's Positive Opinion for Ruxolitinib Viatris

MT Newswires·07/24/2026 07:10:55
Listen to the news
07:10 AM EDT, 07/24/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended the approval of Viatris' (VTRS.VI, VIA.F) Ruxolitinib Viatris. The medicinal product is meant for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease, according to a Friday release. It is a generic of Novartis' (NOVN.SW) Jakavi.